Chris Schott
Stock Analyst at JP Morgan
(1.21)
# 1904
Out of 5,370 analysts
132
Total ratings
52.56%
Success rate
3.78%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Maintains: Overweight | 950 800 | 522.29 | 53.17% | 7 | Jun 9, 2025 | |
TEVA Teva Pharmaceutical ... | Upgrades: Overweight | 21 23 | 17.5 | 31.43% | 10 | May 12, 2025 | |
BIIB Biogen | Maintains: Neutral | 185 175 | 131.07 | 33.52% | 4 | May 5, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 120 130 | 110.72 | 17.41% | 6 | Mar 27, 2025 | |
AMRX Amneal Pharmaceutica... | Upgrades: Overweight | 9 12 | 8.09 | 48.33% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 210 200 | 190.7 | 4.88% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 528.44 | 8.81% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 164.2 | 40.07% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 807.13 | 36.29% | 19 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 10.21 | 95.89% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 26.69 | 53.62% | 8 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 35.09 | 19.69% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 295.12 | -8.51% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 24.39 | 39.4% | 7 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 80.88 | 54.55% | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 8.99 | 55.73% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 0.78 | 1310.26% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 14.01 | 42.76% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 48.55 | 60.66% | 4 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 4.38 | 21589.5% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 24.29 | 105.85% | 3 | Nov 2, 2018 |